Correlation between Molecular Subtype and Clinicopathological Characteristic in Breast Cancer Patients Retrospective Study

Abstract Background Breast cancer is the most common malignancy in women and the fifth cause of cancer mortality worldwide. Breast cancer is a heterogeneous disease characterized by a wide spectrum of many subtypes with distinct biological features that lead to differences in clinicopathological pre...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:QJM : An International Journal of Medicine 2024-10, Vol.117 (Supplement_2)
Hauptverfasser: Elshamely, Shaimaa Hamdy Faried, Sayed Ismaael, Souhair, Tawfik, Amr Shafik, Meckawy, Ghada Refaat, Faheim, Reham Mohamed, Hakem, Sherif Hassanien Ahmed
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Background Breast cancer is the most common malignancy in women and the fifth cause of cancer mortality worldwide. Breast cancer is a heterogeneous disease characterized by a wide spectrum of many subtypes with distinct biological features that lead to differences in clinicopathological presentation. Aim of the Work To correlate clinicopathological characteristics and molecular subtypes and estimate the distribution of breast cancer (BC) subtypes and characteristics. Patients and Methods This is a retrospective study that was conducted on 1413 female patients diagnosed with breast cancer in the Clinical Oncology department, at Ain Shams University Hospital from January 2018 to December 2020 to study the correlation between clinicopathological staging and molecular subtype. Results The study found that luminal A and luminal B HER2-negative were the most common molecular subtypes of breast cancer in the studied population, and there was a significant association between post-menopausal status and these subtypes. There was a significant association between clinical/pathological staging and different molecular subtypes. Patients with higher age or Ki67 > 14% were more likely to have higher stages of breast cancer. Conclusion Molecular subtype of breast carcinoma should routinely be done for all cases of carcinoma breast. They provide valuable information not only about response to therapy but also about possible clinical outcome.
ISSN:1460-2725
1460-2393
DOI:10.1093/qjmed/hcae175.615